These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34838991)

  • 1. Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry.
    Ruyssen-Witrand A; Boudali Y; Pane I; Cantagrel A; Thevenot P; Soubrier M; Morel J; Houvenagel E; Saraux A; Basch A; Truchetet ME; Marotte H; Dernis E; Claudepierre P; Flipo RM; Gottenberg JE; Ravaud P; Mariette X; Seror R
    Joint Bone Spine; 2022 May; 89(3):105310. PubMed ID: 34838991
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
    Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
    Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
    Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
    J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
    Cárdenas M; de la Fuente S; Font P; Castro-Villegas M; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérez J; Escudero-Contreras A; Casado M; Del Prado J; Collantes-Estévez E
    Rheumatol Int; 2016 Feb; 36(2):231-41. PubMed ID: 26494567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
    Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance.
    Colina M; Khodeir M; Rimondini R; Valentini M; Campomori F; Corvaglia S; Campana G
    Clin Drug Investig; 2024 Mar; 44(3):141-148. PubMed ID: 38294672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
    Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
    Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
    [No Abstract]   [Full Text] [Related]  

  • 11. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
    Mengato D; Messori A
    Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
    Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
    Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
    [No Abstract]   [Full Text] [Related]  

  • 14. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
    McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
    Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC
    J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The best practice for TNF inhibitors.].
    Kameda H
    Clin Calcium; 2018; 28(5):655-660. PubMed ID: 29731461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis.
    Fisher A; Bassett K; Goel G; Stanely D; Brookhart MA; Freeman HR; Wright JM; Dormuth CR
    PLoS One; 2016; 11(12):e0168005. PubMed ID: 27930739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study.
    Fisher A; Bassett K; Wright JM; Brookhart MA; Freeman H; Dormuth CR
    PLoS One; 2014; 9(8):e105193. PubMed ID: 25141123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.